Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06151236 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Secondary endpoints: 10 to 11 Eligibility criteria expanded, about 3 wordsv7 Show 1 more changeShow less
    • Eligibility criteria expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  2. Eligibility criteria expanded, about 27 words Secondary endpoints revised (10) · Site contact updatedv6 Show 2 more changesShow less
    • Secondary endpoints revised (10)
    • Site contact updated

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 2 to 1 Eligibility criteria expanded, about 42 words · Secondary endpoints revised (10)v5 Show 2 more changesShow less
    • Eligibility criteria expanded, about 42 words
    • Secondary endpoints revised (10)

    See this version in full on ClinicalTrials.gov ↗

  4. Primary completion date: Apr 2026 to Dec 2026v4
  5. Trial status: Not Yet Recruiting to Recruiting Study sites: 1 to 2 · Start date changed from estimate of Feb 2024 to Mar 11, 2024v3 Show 2 more changesShow less
    • Study sites: 1 to 2
    • Start date changed from estimate of Feb 2024 to Mar 11, 2024
  6. Re-verified, no change to tracked fieldsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to test neoadjuvant dual immunotherapy in Merkel cell carcinoma with the aim to improve recurrence-free survival
Trial Details
NCT Number NCT06151236
Lead Sponsor Melanoma Institute Australia
Collaborators: Bristol-Myers Squibb
Conditions Merkel Cell Carcinoma
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov